Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
MATINS
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
- NCT03733990 ↗
- Completed
- Faron Pharmaceuticals Ltd
- Focused
We haven't built an HCP commentary report on MATINS yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MATINS so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Cancer
- Interventions
- FP-1305 (bexmarilimab)
- Arms
- FP-1305 (bexmarilimab) 0.3 mg/kg · Experimental
- FP-1305 (bexmarilimab) 1 mg/kg · Experimental
- FP-1305 (bexmarilimab) 3 mg/kg · Experimental
- FP-1305 (bexmarilimab) 10 mg/kg · Experimental
- FP-1305 (bexmarilimab) 0.1 mg/kg · Experimental
- FP-1305 (bexmarilimab) 30 mg/kg · Experimental
- Enrollment
- 216
- Primary outcomes
- Dose Limiting Toxicities (DLT) in the Trial Subjects.
- Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)
- The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.
- The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.
- Sponsor
- Faron Pharmaceuticals Ltd
- Start
- Dec 3, 2018
- Primary completion
- Sep 6, 2023
- Results posted
- Yes
- Registry record
- NCT03733990 · updated Apr 2, 2025
Publications
linked from the registry- Rannikko JH, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, Iivanainen S, Shetty S, Ma YT, Graham DM, Arora SP, Jaakkola P, Yap C, Xiang Y, Mandelin J, Karvonen MK, Jalkanen J, Karaman S, Koivunen JP, Minchom A, Hollmen M, Bono P. Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial. Cell Rep Med. 2023 Dec 19;4(12):101307. doi: 10.1016/j.xcrm.2023.101307. Epub 2023 Dec 5. PubMed 38056464
- Hollmen M, Maksimow M, Rannikko JH, Karvonen MK, Vainio M, Jalkanen S, Jalkanen M, Mandelin J. Nonclinical Characterization of Bexmarilimab, a Clever-1-Targeting Antibody for Supporting Immune Defense Against Cancers. Mol Cancer Ther. 2022 Jul 5;21(7):1207-1218. doi: 10.1158/1535-7163.MCT-21-0840. PubMed 35500016
- Virtakoivu R, Rannikko JH, Viitala M, Vaura F, Takeda A, Lonnberg T, Koivunen J, Jaakkola P, Pasanen A, Shetty S, de Jonge MJA, Robbrecht D, Ma YT, Skytta T, Minchom A, Jalkanen S, Karvonen MK, Mandelin J, Bono P, Hollmen M. Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clin Cancer Res. 2021 Aug 1;27(15):4205-4220. doi: 10.1158/1078-0432.CCR-20-4862. Epub 2021 Jun 2. PubMed 34078651